RARE Webinar: Epidermolysis Bullosa Community


Recorded Webinar/Download Slides

The purpose of the webinar is to provide the Epidermolysis Bullosa community with accurate and up to date information on the results of the phase three trial of SD-101. As you know, on September 13th, 2017 Amicus Therapeutics Announced that top-line data from the randomized, double-blind, placebo-controlled Phase 3 clinical study (ESSENCE, SD-005) to assess the efficacy and safety of the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in participants with epidermolysis bullosa (EB). Amicus Therapeutics is committed to ensuring that the Epidermolysis Bullosa community is provided with the results of the phase three trial of SD-101 and would like the opportunity to present this information to the community via webinar.

If you are unable to attend the live webinar, still register so you can receive a link to the recorded content.

Don’t forget, to access this webinar use the password: EBWebinar

  • Welcome and Introduction by Global Genes, Kendall Davis
  • Welcome and Introductions by Amicus Team
  • Results of the phase 3 trial of SD-101 by Dr. Amy Paller
  • Questions and Answers by All
Dr. Amy Paller Director, Northwestern University, Skin Disease Research Center (SDRC)
Jayne Gershkowitz, Cheif Patient Advocate, Amicus Therapeutics
Kendall Davis, MPH, Director of Strategic Alliances, Global Genes